Firm Wire items are announcements made by the firms themselves. The desk confirms that the announcement was published and reproduces its factual content. It does not verify the claims in it, and publication is not an endorsement.
Sidley says it advised Hengrui on a licensing agreement worth up to $2.6 billion
Sidley said it represented Jiangsu Hengrui Pharmaceuticals in a licensing agreement with Novo Nordisk for HRS-1596, a phase 1-ready GLP-1/GIP dual receptor agonist. The firm said the agreement, which includes a $300 million upfront payment, has a potential value of up to $2.6 billion, contingent on development, regulatory and commercial milestones.
Key points
- Sidley said the drug is designed for potential once-weekly oral dosing.Sidley
- The firm said the licensed territory excludes mainland China, Hong Kong, Macao and Taiwan.Sidley
- Sidley said Hengrui is also eligible for royalties on licensed-territory net sales.Sidley
- The firm said Lila Hope, Jennifer Raab and Jiqiang Lin led its team.Sidley